论文部分内容阅读
目的:观察通尿灵治疗良性前列腺增生症(BPH)的临床疗效。方法:选择经临床确诊的良性前列腺增生症患者46例，口服通尿灵50 mg，bid，共8周。分别于治疗前、治疗4周、8周，进行国际前列腺症状评分(IPSS)、最大尿流率(MFR)、残余尿量及前列腺体积等指标测定，同时记录出现的不良反应。结果:用药第8周后IPSS平均降低5.8分，MFR平均升高4.3 ml·s-1，残余尿量平均减少19.5 ml，前列腺体积无明显变化。46例中只有1例出现轻微的消化道不适症状。结论:通尿灵对改善BPH患者主观症状、客观体征和提高生活质量有明显效果，不良反应发生率低。
Objective: To observe the clinical effect of Tongluoling in treating benign prostatic hyperplasia (BPH). Methods: Forty-six patients with clinically diagnosed benign prostatic hyperplasia (BPH) were enrolled in this study. The levels of IPSS, MFR, residual urine volume and prostate volume were measured before treatment, 4 weeks and 8 weeks respectively. The adverse reactions were also recorded. Results: After 8 weeks of treatment, IPSS decreased 5.8 points on average and MFR increased 4.3 ml · s-1 on average, and the residual urine volume decreased by 19.5 ml on average. There was no significant change in the volume of prostate. Only one of 46 patients developed mild gastrointestinal symptoms. Conclusion: Tongluoling has a significant effect on improving subjective symptoms, objective signs and improving quality of life in patients with BPH, with a low incidence of adverse reactions.